Literature DB >> 25695894

Impairment of anaerobic capacity in adults with growth hormone deficiency.

Viral Chikani1, Ross C Cuneo, Ingrid Hickman, Ken K Y Ho.   

Abstract

CONTEXT: The anaerobic energy system underpins the initiation of all physical activities, including those of daily living. GH supplementation improves sprinting in recreational athletes, a performance measure dependent on the anaerobic energy system. The physiological and functional link between GH and the anaerobic energy system is unknown.
OBJECTIVE: The objective was to investigate whether anaerobic capacity is impaired in adults with GH deficiency (GHD) and to assess its functional significance.
DESIGN: This was a cross-sectional study. PARTICIPANTS: The participants were 13 adults with GHD and 13 age-, gender- and body mass index-matched normal subjects. MAIN OUTCOME MEASURES: Anaerobic power (watts) was assessed by the 30-second Wingate test, and aerobic capacity was assessed by the VO2max (L/min) test. The functional assessment comprised the stair-climb test, chair-stand test, and 7-day pedometry. Quality of life (QoL) was assessed by the QoL-AGHDA questionnaire. Lean body mass (LBM) was quantified by dual-energy x-ray absorptiometry.
RESULTS: Mean anaerobic power (5.8 ± 0.4 vs 7.1 ± 0.3 W · kg LBM(-1); P < .05) and VO2max were significantly lower in adults with GHD. The duration of the stair-climb test was longer (19.4 ± 0.7 vs 16.5 ± 0.7 s; P < .01) in adults with GHD and correlated negatively (R(2) = 0.7; P < .0001) with mean anaerobic power. The mean number of chair-stand repetitions and daily step counts were lower, and the QoL-AGHDA score was higher in adults with GHD (P < .05). In a multiple regression analysis, age, gender, LBM, and GH status were significant predictors of mean anaerobic power. Mean anaerobic power significantly predicted stair-climb performance (P < .01) and QoL (P < .05).
CONCLUSIONS: Anaerobic capacity is subnormal, and it independently predicts stair-climbing capacity and QoL in adults with GHD. We conclude that GH regulates anaerobic capacity, which determines QoL and selective aspects of physical function.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25695894     DOI: 10.1210/jc.2015-1006

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Growth hormone therapy in adults with growth hormone deficiency: a critical assessment of the literature.

Authors:  Xin He; Ariel L Barkan
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

2.  Increased Human Growth Hormone After Oral Consumption of an Amino Acid Supplement: Results of a Randomized, Placebo-Controlled, Double-Blind, Crossover Study in Healthy Subjects.

Authors:  Charmaine S Tam; William D Johnson; Jennifer Rood; Amy L Heaton; Frank L Greenway
Journal:  Am J Ther       Date:  2020 Jul/Aug       Impact factor: 3.098

3.  Mechanism for the Increase in Human Growth Hormone with Administration of a Novel Test Supplement and Results Indicating Improved Physical Fitness and Sleep Efficiency.

Authors:  Amy L Heaton; Colleen Kelly; Jennifer Rood; Charmaine S Tam; Frank L Greenway
Journal:  J Med Food       Date:  2020-10-08       Impact factor: 2.542

Review 4.  Targeting growth hormone function: strategies and therapeutic applications.

Authors:  Man Lu; Jack U Flanagan; Ries J Langley; Michael P Hay; Jo K Perry
Journal:  Signal Transduct Target Ther       Date:  2019-02-08

5.  Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone.

Authors:  Fumio Otsuka; Yutaka Takahashi; Shigeyuki Tahara; Yoshihisa Ogawa; Michael Højby Rasmussen; Koji Takano
Journal:  Clin Endocrinol (Oxf)       Date:  2020-08-14       Impact factor: 3.478

6.  A Novel Liver-targeted Testosterone Therapy for Sarcopenia in Androgen Deprived Men With Prostate Cancer.

Authors:  Handoo Rhee; Anojan Navaratnam; Irina Oleinikova; Deborah Gilroy; Yolanda Scuderi; Peter Heathcote; Tuan Nguyen; Simon Wood; Ken K Y Ho
Journal:  J Endocr Soc       Date:  2021-06-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.